{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T14:16:30Z","timestamp":1776262590435,"version":"3.50.1"},"reference-count":50,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["IDDT"],"published-print":{"date-parts":[[2020,5,13]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p> HCV treatment showed dramatical change due to the introduction of potent,\nstrong, direct antiviral drugs. Before the appearance of Direct-acting antivirals, multiple\ntherapeutic interventions were used for hepatitis C, but none of these interventions were effective\non patient-centered outcomes. Direct-acting antivirals cause disruption of viral replication because\nthey target specific nonstructural viral proteins.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Aim:<\/jats:title>\n<jats:p>To review the advantages of efficient HCV therapy and its long term drawbacks.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p> A search of the literature published in indexed databases (PubMed, Medline In-Process,\nand Embase) within the last 5 years was conducted. Any duplicated citations were excluded before\nfirst-pass screening. Citations (titles and abstracts) were screened for eligibility by a single\nreviewer. Full texts (including congress abstracts, posters and other congress communications) of\ncitations deemed relevant during title and abstract screening were retrieved for second-pass review.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Studies on the clinical effects of DAAs for hepatitis C show better tolerance, improved\nsurvival and fewer complications when compared to previous interferon therapy.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p> HCV treatment has improved dramatically. Since that time, there are multiple approved\noral therapies all with high efficacy. The most important factor which should be considered\nduring choosing appropriate therapy is to ensure that it covers the viral genotype of the infected\npatients.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871526519666190121114003","type":"journal-article","created":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T12:46:42Z","timestamp":1569329202000},"page":"143-149","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Hepatitis C Virus: Efficacy of New DAAs Regimens"],"prefix":"10.2174","volume":"20","author":[{"given":"Amal Ahmed","family":"Mohamed","sequence":"first","affiliation":[{"name":"Biochemistry and Molecular Biology Department, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naglaa El-Toukhy Ramadan","family":"El-Toukhy","sequence":"additional","affiliation":[{"name":"Hepatology, Gastroenterology and Infectious Diseases Department, Benha Faculty of Medicine, Benha University, Banha, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ebada Mohamed","family":"Said","sequence":"additional","affiliation":[{"name":"Hepatology, Gastroenterology and Infectious Diseases Department, Benha Faculty of Medicine, Benha University, Banha, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoda Mohamed Rabie","family":"Gabal","sequence":"additional","affiliation":[{"name":"Hepatology, Gastroenterology and Infectious Diseases Department, Benha Faculty of Medicine, Benha University, Banha, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossameldin","family":"AbdelAziz","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wahid","family":"Doss","sequence":"additional","affiliation":[{"name":"Department of Tropical Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadeel","family":"El-Hanafi","sequence":"additional","affiliation":[{"name":"Clinical and Chemical Pathology, Kasr El-Einy Hospitals, Cairo University, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hala H.","family":"El Deeb","sequence":"additional","affiliation":[{"name":"Clnical Pathology department, El Sahel Teaching Hospital, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seham","family":"Mahmoud","sequence":"additional","affiliation":[{"name":"Tropical Medicine Department, El Sahel Teaching Hospital, Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Elkadeem","sequence":"additional","affiliation":[{"name":"Tropical Medicine Department, Tanta University, Tanta, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan Salama","family":"Shalby","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Faculty of Medicine, Misr Science and Technology University, Giza, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherief","family":"Abd-Elsalam","sequence":"additional","affiliation":[{"name":"Tropical Medicine Department, Tanta University, Tanta, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","year":"2017","unstructured":"WHO Hepatitis C WHO fact sheet N 164 Available from: 2017","journal-title":"Hepatitis C WHO fact sheet N 164"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"Manns M.P.","year":"2001","unstructured":"Manns M.P.; McHutchison J.G.; Gordon S.C.; Rustgi V.K.; Shiffman M.; Reindollar R.; Goodman Z.D.; Koury K.; Ling M.; Albrecht J.K.; Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001,358(9286),958-965","journal-title":"Lancet"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"Fried M.W.","year":"2002","unstructured":"Fried M.W.; Shiffman M.L.; Reddy K.R.; Smith C.; Marinos G.; Gon\u00e7ales F.L.; H\u00e4ussinger D.; Diago M.; Carosi G.; Dhumeaux D.; Craxi A.; Lin A.; Hoffman J.; Yu J.; Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002,347(13),975-982","journal-title":"N Engl J Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.pharmthera.2017.10.009","volume":"183","author":"Spengler U.","year":"2017","unstructured":"Spengler U.; Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection. Pharmacol Ther 2017,183,118-126","journal-title":"Pharmacol Ther"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2174\/1871526517666170417143216","volume":"17","author":"Ahmed O.A.","year":"2017","unstructured":"Ahmed O.A.; Kaisar H.H.; Hawash N.; Samir H.; Shabana S.S.T.; Hassan A Fouad M.; Rizk F.; Abd-Elsalam S.; Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in treatment of a cohort of Egyptian patients with hepatitis C virus infection. Infect Disord Drug Targets 2017,17(2),95-100","journal-title":"Infect Disord Drug Targets"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00705-017-3573-0","volume":"163","author":"Abd-Elsalam S.","year":"2018","unstructured":"Abd-Elsalam S.; Sharaf-Eldin M.; Soliman S.; Elfert A.; Badawi R.; Ahmad Y.K.; Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice. Arch Virol 2018,163(1),51-56","journal-title":"Arch Virol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2147\/IDR.S160593","volume":"11","author":"Ahmed O.A.","year":"2018","unstructured":"Ahmed O.A.; Elsebaey M.A.; Fouad M.H.A.; Elashry H.; Elshafie A.I.; Elhadidy A.A.; Esheba N.E.; Elnaggar M.H.; Soliman S.; Abd-Elsalam S.; Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection. Infect Drug Resist 2018,11,441-445","journal-title":"Infect Drug Resist"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/IDR.S153060","volume":"11","author":"Ahmed O.A.","year":"2018","unstructured":"Ahmed O.A.; Kaisar H.H.; Badawi R.; Hawash N.; Samir H.; Shabana S.S.; Fouad M.H.A.; Rizk F.H.; Khodeir S.A.; Abd-Elsalam S.; Efficacy and safety of sofosbuvir-ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection. Infect Drug Resist 2018,11,295-298","journal-title":"Infect Drug Resist"},{"key":"ref=9","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9616234","volume":"2018","author":"Ahmed O.A.","year":"2018","unstructured":"Ahmed O.A.; Safwat E.; Khalifa M.O.; Elshafie A.I.; Fouad M.H.A.; Salama M.M.; Naguib G.G.; Eltabbakh M.M.; Sherief A.F.; Abd-Elsalam S.; Sofosbuvir Plus daclatasvir in treatment of chronic hepatitis C genotype 4 infection in a cohort of egyptian patients: An experiment the size of egyptian village. Int J Hepatol 2018,2018","journal-title":"Int J Hepatol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"584","DOI":"10.2174\/1389557517666170913111930","volume":"18","author":"Das D.","year":"2018","unstructured":"Das D.; Pandya M.; Recent advancement of Direct-acting antiviral agents (DAAs) in Hepatitis C therapy. Mini Rev Med Chem 2018,18(7),584-596","journal-title":"Mini Rev Med Chem"},{"key":"ref=11","year":"2016","unstructured":"WHO.WHO Guidelines for the screening, care and treatment of persons with hepatitis C infection updated version april 2016  Available from: 2016","journal-title":"Guidelines for the screening, care and treatment of persons with hepatitis C infection updated version april 2016"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1128\/JVI.67.7.3835-3844.1993","volume":"67","author":"Bartenschlager R.","year":"1993","unstructured":"Bartenschlager R.; Ahlborn-Laake L.; Mous J.; Jacobsen H.; Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3\/4 and NS4\/5 junctions. J Virol 1993,67(7),3835-3844","journal-title":"J Virol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/j.1365-2893.2012.01617.x","volume":"19","author":"Poordad F.","year":"2012","unstructured":"Poordad F.; Dieterich D.; Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J Viral Hepat 2012,19(7),449-464","journal-title":"J Viral Hepat"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/MOG.0000000000000350","volume":"33","author":"Behara R.","year":"2017","unstructured":"Behara R.; Reau N.; Updates on hepatitis C virus therapy in the direct-acting antiviral era. Curr Opin Gastroenterol 2017,33(3),115-119","journal-title":"Curr Opin Gastroenterol"},{"key":"ref=15","unstructured":"FDA. 2017:FDA approves Vosevi for Hepatitis C, Available from:","journal-title":"approves Vosevi for Hepatitis C,"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/hep.28422","volume":"64","author":"Lawitz E.","year":"2016","unstructured":"Lawitz E.; Matusow G.; DeJesus E.; Yoshida E.M.; Felizarta F.; Ghalib R.; Godofsky E.; Herring R.W.; Poleynard G.; Sheikh A.; Tobias H.; Kugelmas M.; Kalmeijer R.; Peeters M.; Lenz O.; Fevery B.; De La Rosa G.; Scott J.; Sinha R.; Witek J.; Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2). Hepatology 2016,64(2),360-369","journal-title":"Hepatology"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1053\/j.gastro.2016.07.039","volume":"151","author":"Lawitz E.","year":"2016","unstructured":"Lawitz E.; Reau N.; Hinestrosa F.; Rabinovitz M.; Schiff E.; Sheikh A.; Younes Z.; Herring R.; Reddy K.R.; Tran T.; Bennett M.; Nahass R.; Yang J.C.; Lu S.; Dvory-Sobol H.; Stamm L.M.; Brainard D.M.; McHutchison J.G.; Pearlman B.; Shiffman M.; Hawkins T.; Curry M.; Jacobson I.; Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with genotype 1 hepatitis C virus infection in an openlabel, phase 2 trial. Gastroenterology 2016,151(5),893-901.e1","journal-title":"Gastroenterology"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","volume":"384","author":"Lawitz E.","year":"2014","unstructured":"Lawitz E.; Sulkowski M.S.; Ghalib R.; Rodriguez-Torres M.; Younossi Z.M.; Corregidor A.; DeJesus E.; Pearlman B.; Rabinovitz M.; Gitlin N.; Lim J.K.; Pockros P.J.; Scott J.D.; Fevery B.; Lambrecht T.; Ouwerkerk-Mahadevan S.; Callewaert K.; Symonds W.T.; Picchio G.; Lindsay K.L.; Beumont M.; Jacobson I.M.; Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014,384(9956),1756-1765","journal-title":"Lancet"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","volume":"370","author":"Afdhal N.","year":"2014","unstructured":"Afdhal N.; Reddy K.R.; Nelson D.R.; Lawitz E.; Gordon S.C.; Schiff E.; Nahass R.; Ghalib R.; Gitlin N.; Herring R.; Lalezari J.; Younes Z.H.; Pockros P.J.; Di Bisceglie A.M.; Arora S.; Subramanian G.M.; Zhu Y.; Dvory-Sobol H.; Yang J.C.; Pang P.S.; Symonds W.T.; McHutchison J.G.; Muir A.J.; Sulkowski M.; Kwo P.;  ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014,370(16),1483-1493","journal-title":"N Engl J Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","volume":"370","author":"Afdhal N.","year":"2014","unstructured":"Afdhal N.; Zeuzem S.; Kwo P.; Chojkier M.; Gitlin N.; Puoti M.; Romero-Gomez M.; Zarski J.P.; Agarwal K.; Buggisch P.; Foster G.R.; Br\u00e4u N.; Buti M.; Jacobson I.M.; Subramanian G.M.; Ding X.; Mo H.; Yang J.C.; Pang P.S.; Symonds W.T.; McHutchison J.G.; Muir A.J.; Mangia A.; Marcellin P.;  ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014,370(20),1889-1898","journal-title":"N Engl J Med"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/hep.27826","volume":"62","author":"Reddy K.R.","year":"2015","unstructured":"Reddy K.R.; Bourli\u00e8re M.; Sulkowski M.; Omata M.; Zeuzem S.; Feld J.J.; Lawitz E.; Marcellin P.; Welzel T.M.; Hyland R.; Ding X.; Yang J.; Knox S.; Pang P.; Dvory-Sobol H.; Subramanian G.M.; Symonds W.; McHutchison J.G.; Mangia A.; Gane E.; Mizokami M.; Pol S.; Afdhal N.; Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Hepatology 2015,62(1),79-86","journal-title":"Hepatology"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","volume":"66","year":"2017","unstructured":"European Association for the Study of the Liver.  J Hepatol 2017,66(1),153-194","journal-title":"J Hepatol"},{"key":"ref=23","year":"2017","unstructured":"The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America Present: HCV guidance:recommendations for testing, managing, and treating hepatitis C.2014-2018 AASLD and IDSA, 2017"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","volume":"63","author":"Pawlotsky J.M.","year":"2015","unstructured":"Pawlotsky J.M.; Aghemo A.; Back D.; European association for study of liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015,63(1),199-236","journal-title":"J Hepatol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","volume":"370","author":"Kowdley K.V.","year":"2014","unstructured":"Kowdley K.V.; Gordon S.C.; Reddy K.R.; Rossaro L.; Bernstein D.E.; Lawitz E.; Shiffman M.L.; Schiff E.; Ghalib R.; Ryan M.; Rustgi V.; Chojkier M.; Herring R.; Di Bisceglie A.M.; Pockros P.J.; Subramanian G.M.; An D.; Svarovskaia E.; Hyland R.H.; Pang P.S.; Symonds W.T.; McHutchison J.G.; Muir A.J.; Pound D.; Fried M.W.;  ION-3 Investigators.Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014,370(20),1879-1888","journal-title":"N Engl J Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3851\/IMP3117","volume":"22","author":"Backus L.I.","year":"2017","unstructured":"Backus L.I.; Belperio P.S.; Shahoumian T.A.; Loomis T.P.; Mole L.A.; Real-world effectiveness and predictors of sustained virological response with all-oral therapy in 21,242 hepatitis C genotype-1 patients. Antivir Ther (Lond) 2017,22(6),481-493","journal-title":"Antivir Ther (Lond)"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/cid\/ciw567","volume":"63","author":"Ingiliz P.","year":"2016","unstructured":"Ingiliz P.; Christensen S.; Kimhofer T.; Hueppe D.; Lutz T.; Schewe K.; Busch H.; Schmutz G.; Wehmeyer M.H.; Boesecke C.; Simon K.G.; Berger F.; Rockstroh J.K.; Schulze zur Wiesch J.; Baumgarten A.; Mauss S.; Sofosbuvir and ledipasvir for 8 weeks for the treatment of chronic hepatitis C virus (HCV) Infection in HCV-monoinfected and HIV-HCV-coinfected individuals: Results from the german hepatitis C cohort (GECCO-01). Clin Infect Dis 2016,63(10),1320-1324","journal-title":"Clin Infect Dis"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1053\/j.gastro.2016.05.049","volume":"151","author":"Ioannou G.N.","year":"2016","unstructured":"Ioannou G.N.; Beste L.A.; Chang M.F.; Green P.K.; Lowy E.; Tsui J.I.; Su F.; Berry K.; Effectiveness of sofosbuvir, ledipasvir\/sofosbuvir, or paritaprevir\/ritonavir\/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis c in the veterans affairs national health care system. Gastroenterology 2016,151(3),457-471.e5","journal-title":"Gastroenterology"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/hep.29005","volume":"65","author":"Kowdley K.V.","year":"2017","unstructured":"Kowdley K.V.; Sundaram V.; Jeon C.Y.; Eight weeks of ledipasvir\/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection. Hepatology 2017,65(4),1094-1103","journal-title":"Hepatology"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1053\/j.gastro.2016.08.004","volume":"151","author":"Terrault N.A.","year":"2016","unstructured":"Terrault N.A.; Zeuzem S.; Di Bisceglie A.M.; Lim J.K.; Pockros P.J.; Frazier L.M.; Kuo A.; Lok A.S.; Shiffman M.L.; Ben Ari Z.; Akushevich L.; Vainorius M.; Sulkowski M.S.; Fried M.W.; Nelson D.R.;  HCV-TARGET Study Group.Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. Gastroenterology 2016,151(6),1131-1140.e5","journal-title":"Gastroenterology"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/hep.28901","volume":"65","author":"Su F.","year":"2017","unstructured":"Su F.; Green P.K.; Berry K.; Ioannou G.N.; The association between race\/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection. Hepatology 2017,65(2),426-438","journal-title":"Hepatology"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/hep.28334","volume":"63","author":"Wilder J.M.","year":"2016","unstructured":"Wilder J.M.; Jeffers L.J.; Ravendhran N.; Shiffman M.L.; Poulos J.; Sulkowski M.S.; Gitlin N.; Workowski K.; Zhu Y.; Yang J.C.; Pang P.S.; McHutchison J.G.; Muir A.J.; Howell C.; Kowdley K.; Afdhal N.; Reddy K.R.; Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data. Hepatology 2016,63(2),437-444","journal-title":"Hepatology"},{"key":"ref=33","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofu110","volume":"1","author":"O\u2019Brien T.R.","year":"2014","unstructured":"O\u2019Brien T.R.; Lang Kuhs K.A.; Pfeiffer R.M.; Subgroup differences in response to 8 weeks of ledipasvir\/sofosbuvir for chronic hepatitis C. Open Forum Infect Dis 2014,1(3)","journal-title":"Open Forum Infect Dis"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","volume":"370","author":"Feld J.J.","year":"2014","unstructured":"Feld J.J.; Kowdley K.V.; Coakley E.; Sigal S.; Nelson D.R.; Crawford D.; Weiland O.; Aguilar H.; Xiong J.; Pilot-Matias T.; DaSilva-Tillmann B.; Larsen L.; Podsadecki T.; Bernstein B.; Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014,370(17),1594-1603","journal-title":"N Engl J Med"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","volume":"370","author":"Ferenci P.","year":"2014","unstructured":"Ferenci P.; Bernstein D.; Lalezari J.; Cohen D.; Luo Y.; Cooper C.; Tam E.; Marinho R.T.; Tsai N.; Nyberg A.; Box T.D.; Younes Z.; Enayati P.; Green S.; Baruch Y.; Bhandari B.R.; Caruntu F.A.; Sepe T.; Chulanov V.; Janczewska E.; Rizzardini G.; Gervain J.; Planas R.; Moreno C.; Hassanein T.; Xie W.; King M.; Podsadecki T.; Reddy K.R.; PEARL-III Study; PEARL-IV Study.ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014,370(21),1983-1992","journal-title":"N Engl J Med"},{"key":"ref=36","year":"2017","unstructured":"AbbVieInc. VIEKIRA XR (dasabuvir, ombitasvir, paritaprevir, and ritonavir) [Package insert]., 2017"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/M15-0785","volume":"163","author":"Zeuzem S.","year":"2015","unstructured":"Zeuzem S.; Ghalib R.; Reddy K.R.; Pockros P.J.; Ben Ari Z.; Zhao Y.; Brown D.D.; Wan S.; DiNubile M.J.; Nguyen B.Y.; Robertson M.N.; Wahl J.; Barr E.; Butterton J.R.; Grazoprevir-Elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 2015,163(1),1-13","journal-title":"Ann Intern Med"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S0140-6736(14)61793-1","volume":"385","author":"Sulkowski M.S.","year":"2015","unstructured":"Sulkowski M.S.; H\u00e9zode C.; Gerstoft J.; Vierling J.M.; Mallolas J.; Pol S.; Efficacy and safety of 8 wks versus 12 wks oftreatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with HCV GT1 mono-infection and HIV\/HCV coinfection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015,385(9973),1087-1097","journal-title":"Lancet"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.jhep.2017.01.007","volume":"66","author":"Zeuzem S.","year":"2017","unstructured":"Zeuzem S.; Mizokami M.; Pianko S.; Mangia A.; Han K.H.; Martin R.; Svarovskaia E.; Dvory-Sobol H.; Doehle B.; Hedskog C.; Yun C.; Brainard D.M.; Knox S.; McHutchison J.G.; Miller M.D.; Mo H.; Chuang W.L.; Jacobson I.; Dore G.J.; Sulkowski M.; NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome. J Hepatol 2017,66(5),910-918","journal-title":"J Hepatol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1053\/j.gastro.2016.09.045","volume":"152","author":"Kwo P.","year":"2017","unstructured":"Kwo P.; Gane E.J.; Peng C.Y.; Pearlman B.; Vierling J.M.; Serfaty L.; Buti M.; Shafran S.; Stryszak P.; Lin L.; Gress J.; Black S.; Dutko F.J.; Robertson M.; Wahl J.; Lupinacci L.; Barr E.; Haber B.; effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology 2017,152(1),164-175.e4","journal-title":"Gastroenterology"},{"key":"ref=41","author":"Jacobson I.M.","year":"2015","unstructured":"Jacobson I.M.; Asante-Appiah E.; Wong P.; Black T.; Howe A.; Wahl J.; Prevalence and impact of baseline NSA resistance associated variants (RAVs) on the efficacy of elbasvir\/grazoprevir (EBR\/GZR) against GT1a infection [abstract lb-22]. 66th annual meeting of the American Association For The Study Of Liver Diseases (AASLD), November 13-17, 2015., 2015"},{"key":"ref=42","author":"Thompson A.","year":"2015","unstructured":"Thompson A.; Zeuzem S.; Rockstroh J.K.; Kwo P.Y.; Roth D.; Lawitz E.J.; The combination of Grazoprevir and Elbasvir +RBV is highly effective for the treatment of GT1a-Infected patients. American Association for the Study of Liver Diseases., The Liver Meeting.San Francisco, CA, USA, 2015"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","volume":"67","author":"Kwo P.Y.","year":"2017","unstructured":"Kwo P.Y.; Poordad F.; Asatryan A.; Wang S.; Wyles D.L.; Hassanein T.; Felizarta F.; Sulkowski M.S.; Gane E.; Maliakkal B.; Overcash J.S.; Gordon S.C.; Muir A.J.; Aguilar H.; Agarwal K.; Dore G.J.; Lin C.W.; Liu R.; Lovell S.S.; Ng T.I.; Kort J.; Mensa F.J.; Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol 2017,67(2),263-271","journal-title":"J Hepatol"},{"key":"ref=44","author":"Zeuzem S.","unstructured":"Zeuzem S.; Feld J.; Wang S.; ENDURANCE-1: Efficacy and safety of 8- versus 12-week treatment with ABT-493\/ABT-530 in patients with chronic HCV genotype 1 infection [Abstract 253]. 67th Annual Meeting of the American Association for the Study of Liver diseases","journal-title":"67th Annual Meeting of the American Association for the Study of Liver diseases"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","volume":"17","author":"Forns X.","year":"2017","unstructured":"Forns X.; Lee S.S.; Valdes J.; Lens S.; Ghalib R.; Aguilar H.; Felizarta F.; Hassanein T.; Hinrichsen H.; Rincon D.; Morillas R.; Zeuzem S.; Horsmans Y.; Nelson D.R.; Yu Y.; Krishnan P.; Lin C.W.; Kort J.J.; Mensa F.J.; Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 2017,17(10),1062-1068","journal-title":"Lancet Infect Dis"},{"key":"ref=46","author":"Rockstroh J.","year":"2017","unstructured":"Rockstroh J.; Lacombe K.; Viani R.M.; Orkin C.; Wyles D.; Luetkemeyer A.; Efficacy and safety of Glecaprevir\/Pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 Study [Abstract LBP-522]. International Liver Congress 2017","journal-title":"International Liver Congress"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/hep.28467","volume":"64","author":"Kwo P.","year":"2016","unstructured":"Kwo P.; Gitlin N.; Nahass R.; Bernstein D.; Etzkorn K.; Rojter S.; Schiff E.; Davis M.; Ruane P.; Younes Z.; Kalmeijer R.; Sinha R.; Peeters M.; Lenz O.; Fevery B.; De La Rosa G.; Scott J.; Witek J.; Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology 2016,64(2),370-380","journal-title":"Hepatology"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1056\/NEJMoa1503153","volume":"373","author":"Wyles D.L.","year":"2015","unstructured":"Wyles D.L.; Ruane P.J.; Sulkowski M.S.; Dieterich D.; Luetkemeyer A.; Morgan T.R.; Sherman K.E.; Dretler R.; Fishbein D.; Gathe J.C.; Henn S.; Hinestrosa F.; Huynh C.; McDonald C.; Mills A.; Overton E.T.; Ramgopal M.; Rashbaum B.; Ray G.; Scarsella A.; Yozviak J.; McPhee F.; Liu Z.; Hughes E.; Yin P.D.; Noviello S.; Ackerman P.; ALLY-2 Investigators. Daclatasvir plus sofosbuvir for HCV inpatients coinfected with HIV-1. N Engl J Med 2015,373(8),714-725","journal-title":"N Engl J Med"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1306218","volume":"370","author":"Sulkowski M.S.","year":"2014","unstructured":"Sulkowski M.S.; Gardiner D.F.; Rodriguez-Torres M.; Reddy K.R.; Hassanein T.; Jacobson I.; Lawitz E.; Lok A.S.; Hinestrosa F.; Thuluvath P.J.; Schwartz H.; Nelson D.R.; Everson G.T.; Eley T.; Wind-Rotolo M.; Huang S.P.; Gao M.; Hernandez D.; McPhee F.; Sherman D.; Hindes R.; Symonds W.; Pasquinelli C.; Grasela D.M.; AI444040 Study Group.Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014,370(3),211-221","journal-title":"N Engl J Med"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/hep.27053","volume":"60","author":"Wyles D.L.","year":"2014","unstructured":"Wyles D.L.; Rodriguez-Torres M.; Lawitz E.; Shiffman M.L.; Pol S.; Herring R.W.; Massetto B.; Kanwar B.; Trenkle J.D.; Pang P.S.; Zhu Y.; Mo H.; Brainard D.M.; Subramanian G.M.; McHutchison J.G.; Habersetzer F.; Sulkowski M.S.; All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-na\u00efve patients with genotype 1 HCV infection. Hepatology 2014,60(1),56-64","journal-title":"Hepatology"}],"container-title":["Infectious Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/169198","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T07:11:25Z","timestamp":1594969885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/169198\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,13]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,5,13]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871526519666190121114003","relation":{},"ISSN":["1871-5265"],"issn-type":[{"value":"1871-5265","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,13]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-12-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}